학술논문

A Point-of-Care Faecal Test Combining Four Biomarkers Allows Avoidance of Normal Colonoscopies and Prioritizes Symptomatic Patients with a High Risk of Colorectal Cancer.
Document Type
Article
Source
Cancers. Feb2023, Vol. 15 Issue 3, p721. 14p.
Subject
*FECAL analysis
*COLONOSCOPY
*NERVE tissue proteins
*POINT-of-care testing
*IMMUNOHISTOCHEMISTRY
*COLORECTAL cancer
*MEDICAL care use
*TUMOR markers
*SENSITIVITY & specificity (Statistics)
*FECAL occult blood tests
*CALCIUM-binding proteins
*HEALTH planning
*DISEASE risk factors
*SYMPTOMS
Language
ISSN
2072-6694
Abstract
Simple Summary: Gastrointestinal symptoms are a common reason for endoscopic referral. Symptoms alone are unreliable predictors of colorectal cancer (CRC), but as CRC prognosis relies mainly in an early diagnosis, many of these patients undergo colonoscopy. Therefore, most colonoscopies performed in this setting are normal, exposing these patients to endoscopy-related risks and increasing the workload of endoscopic units. This work analyses a point-of-care (POC) qualitative faecal test that simultaneously detect four biomarkers, comparing it with a quantitative occult blood and calprotectin tests, in stool samples of symptomatic patients referred for colonoscopy. Our results indicate that the POC test may be a useful strategy to triage symptomatic patients, as patients with a negative result in the four biomarkers have a low probability of relevant pathology (94.8–100% for CRC). Moreover, a positive result in the four biomarkers was associated with high risk of serious pathology (70.6% were diagnosed with CRC or inflammatory bowel disease). Most colonoscopies performed to evaluate gastrointestinal symptoms detect only non-relevant pathologies. We aimed to evaluate the diagnostic accuracy of a qualitative point-of-care (POC) test combining four biomarkers (haemoglobin, transferrin, calprotectin, and lactoferrin), a quantitative faecal immunochemical test (FIT) for haemoglobin, and a quantitative faecal calprotectin (FC) test in symptomatic patients prospectively recruited. Colorectal cancer (CRC), adenoma requiring surveillance, inflammatory bowel disease (IBD), microscopic colitis, and angiodysplasia were considered significant pathologies. A total of 571 patients were included. Significant pathology was diagnosed in 118 (20.7%), including 30 CRC cases (5.3%). The POC test yielded the highest negative predictive values: 94.8% for a significant pathology and 100% for CRC or IBD if the four markers turned negative (36.8% of the patients). Negative predictive values of FIT, FC, and its combination for diagnosis of a significant pathology were 88.4%, 87.6%, and 90.8%, respectively. Moreover, the positive predictive value using the POC test was 82.3% for significant pathology when all biomarkers tested positive (6% of the patients), with 70.6% of these patients diagnosed with CRC or IBD. The AUC of the POC test was 0.801 (95%CI 0.754-0.848) for the diagnosis of a significant pathology. Therefore, this POC faecal test allows the avoidance of unnecessary colonoscopies and prioritizes high risk symptomatic patients. [ABSTRACT FROM AUTHOR]